THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced that it has completed its previously announced public offering of 3,500,000 shares of common stock at a price to the public of $2.00 per share and 3,500,000 Series E warrants to purchase shares of common stock exercisable at $2.00 per share at a price of $0.15 per warrant. The Company has granted a 30-day option to the underwriters to purchase up to an additional 15% of the offering to cover over-allotments, and the underwriters have exercised the over-allotment option for 525,000 Series E warrants. The net proceeds to the company of the offering, which included the exercise in full of the over-allotment option for the warrants, were $6.8 million after payment of underwriting discounts and commissions, but excluding estimated offering expenses.
